-
1
-
-
0037087144
-
Hepatitis c virus prevalence among patients infected with human immunodeficiency virus: A crosssectional analysis of the us adult aids clinical trials group
-
Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a crosssectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis 2002; 34:831-837
-
(2002)
Clin Infect Dis
, vol.34
, pp. 831-837
-
-
Sherman, K.E.1
Rouster, S.D.2
Chung, R.T.3
Rajicic, N.4
-
2
-
-
3343012408
-
Peginterferon alfa-2a plus ribavirin for chronic hepatitis c virus infection in hiv-infected patients
-
APRICOT Study Group
-
Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-García J, Lazzarin A, et al. APRICOT Study Group. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351:438-450
-
(2004)
N Engl J Med
, vol.351
, pp. 438-450
-
-
Torriani, F.J.1
Rodriguez-Torres, M.2
Rockstroh, J.K.3
Lissen, E.4
Gonzalez-García, J.5
Lazzarin, A.6
-
3
-
-
3342892905
-
Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis c in hiv-coinfected persons
-
Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, Sherman KE, et al. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004; 351:451-459
-
(2004)
N Engl J Med
, vol.351
, pp. 451-459
-
-
Chung, R.T.1
Andersen, J.2
Volberding, P.3
Robbins, G.K.4
Liu, T.5
Sherman, K.E.6
-
4
-
-
84879799809
-
Combination therapy with telaprevir for chronic hepatitis c virus genotype 1 infection in patients with hiv: A randomized trial
-
Sulkowski MS, Sherman KE, Dieterich DT, Bsharat M, Mahnke L, Rockstroh JK, et al. Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Ann Intern Med 2013; 159:86-96
-
(2013)
Ann Intern Med
, vol.159
, pp. 86-96
-
-
Sulkowski, M.S.1
Sherman, K.E.2
Dieterich, D.T.3
Bsharat, M.4
Mahnke, L.5
Rockstroh, J.K.6
-
5
-
-
84879795434
-
Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis c virus genotype 1 in patients with hiv: A randomised, double-blind, controlled phase 2 trial
-
Sulkowski M, Pol S, Mallolas J, Fainboim H, Cooper C, Slim J, et al. Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial. Lancet Infect Dis 2013; 13:597-605
-
(2013)
Lancet Infect Dis
, vol.13
, pp. 597-605
-
-
Sulkowski, M.1
Pol, S.2
Mallolas, J.3
Fainboim, H.4
Cooper, C.5
Slim, J.6
-
6
-
-
84891835213
-
Virological response rates for telaprevir-based hepatitis c triple therapy in patients with and without hiv coinfection
-
Martel-Laferrière V, Brinkley S, Bichoupan K, Posner S, Stivala A, Perumalswami P, et al. Virological response rates for telaprevir-based hepatitis C triple therapy in patients with and without HIV coinfection. HIV Med 2014; 15:108-115
-
(2014)
HIV Med
, vol.15
, pp. 108-115
-
-
Martel-Laferrière, V.1
Brinkley, S.2
Bichoupan, K.3
Posner, S.4
Stivala, A.5
Perumalswami, P.6
-
7
-
-
84901633131
-
Comparative effectiveness of telaprevir-based triple therapy in patients with chronic hepatitis c
-
Al-Bawardy B, Kim WR, Poterucha JJ, Gross JB, Charlton MR, Larson JJ, et al. Comparative effectiveness of telaprevir-based triple therapy in patients with chronic hepatitis C. Mayo Clin Proc 2014; 89:595-601
-
(2014)
Mayo Clin Proc
, vol.89
, pp. 595-601
-
-
Al-Bawardy, B.1
Kim, W.R.2
Poterucha, J.J.3
Gross, J.B.4
Charlton, M.R.5
Larson, J.J.6
-
8
-
-
37549057972
-
The validity of viral hepatitis and chronic liver disease diagnoses in veterans affairs administrative databases
-
Kramer JR, Davila JA, Miller ED, Richardson P, Giordano TP, El-Serag HB. The validity of viral hepatitis and chronic liver disease diagnoses in Veterans Affairs administrative databases. Aliment Pharmacol Ther 2008; 27:274-282
-
(2008)
Aliment Pharmacol Ther
, vol.27
, pp. 274-282
-
-
Kramer, J.R.1
Davila, J.A.2
Miller, E.D.3
Richardson, P.4
Giordano, T.P.5
El-Serag, H.B.6
-
9
-
-
13744255153
-
The effect of hiv coinfection on the risk of cirrhosis and hepatocellular carcinoma in us veterans with hepatitis c
-
Kramer JR, Giordano TP, Souchek J, Richardson P, Hwang LY, El-Serag HB. The effect of HIV coinfection on the risk of cirrhosis and hepatocellular carcinoma in U.S. veterans with hepatitis C. Am J Gastroenterol 2005; 100:56-63
-
(2005)
Am J Gastroenterol
, vol.100
, pp. 56-63
-
-
Kramer, J.R.1
Giordano, T.P.2
Souchek, J.3
Richardson, P.4
Hwang, L.Y.5
El-Serag, H.B.6
-
10
-
-
34547143659
-
Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis
-
945.e1-4, 945 e931-934
-
Ioannou GN, Splan MF, Weiss NS, McDonald GB, Beretta L, Lee SP. Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol 2007; 5:938-945, 945.e1-4, 945 e931-934
-
(2007)
Clin Gastroenterol Hepatol
, vol.5
, pp. 938-945
-
-
Ioannou, G.N.1
Splan, M.F.2
Weiss, N.S.3
McDonald, G.B.4
Beretta, L.5
Lee, S.P.6
-
11
-
-
79551648518
-
Utilization of surveillance for hepatocellular carcinoma among hepatitis c virus-infected veterans in the united states
-
Davila JA, Henderson L, Kramer JR, Kanwal F, Richardson PA, Duan Z, El-Serag HB. Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States. Ann Intern Med 2011; 154:85-93
-
(2011)
Ann Intern Med
, vol.154
, pp. 85-93
-
-
Davila, J.A.1
Henderson, L.2
Kramer, J.R.3
Kanwal, F.4
Richardson, P.A.5
Duan, Z.6
El-Serag, H.B.7
-
12
-
-
84872144438
-
The prevalence of cirrhosis and hepatocellular carcinoma in patients with human immunodeficiency virus infection
-
Ioannou GN, Bryson CL, Weiss NS, Miller R, Scott JD, Boyko EJ. The prevalence of cirrhosis and hepatocellular carcinoma in patients with human immunodeficiency virus infection. Hepatology 2013; 57:249-257
-
(2013)
Hepatology
, vol.57
, pp. 249-257
-
-
Ioannou, G.N.1
Bryson, C.L.2
Weiss, N.S.3
Miller, R.4
Scott, J.D.5
Boyko, E.J.6
-
13
-
-
0042265556
-
A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis c
-
Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, Lok AS. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38:518-526
-
(2003)
Hepatology
, vol.38
, pp. 518-526
-
-
Wai, C.T.1
Greenson, J.K.2
Fontana, R.J.3
Kalbfleisch, J.D.4
Marrero, J.A.5
Conjeevaram, H.S.6
Lok, A.S.7
-
14
-
-
34547483053
-
FIB-4: An inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest
-
Vallet-Pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, Dhalluin-Venier V, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology 2007; 46:32-36
-
(2007)
Hepatology
, vol.46
, pp. 32-36
-
-
Vallet-Pichard, A.1
Mallet, V.2
Nalpas, B.3
Verkarre, V.4
Nalpas, A.5
Dhalluin-Venier, V.6
-
15
-
-
12444311293
-
Twelve weeks of follow-up is sufficient for the determination of sustained virologic response in patients treated with interferon alpha for chronic hepatitis c
-
Zeuzem S, Heathcote EJ, Shiffman ML, Wright TL, Bain VG, Sherman M, et al. Twelve weeks of follow-up is sufficient for the determination of sustained virologic response in patients treated with interferon alpha for chronic hepatitis C. J Hepatol 2003; 39:106-111
-
(2003)
J Hepatol
, vol.39
, pp. 106-111
-
-
Zeuzem, S.1
Heathcote, E.J.2
Shiffman, M.L.3
Wright, T.L.4
Bain, V.G.5
Sherman, M.6
-
16
-
-
84904393872
-
Similar effectiveness of boceprevir and telaprevir treatment regimens for hepatitis c virus infection on the basis of a nationwide study of veterans
-
Ioannou GN, Beste LA, Green PK. Similar effectiveness of boceprevir and telaprevir treatment regimens for hepatitis C virus infection on the basis of a nationwide study of veterans. Clin Gastroenterol Hepatol 2014; 12:1371-1380
-
(2014)
Clin Gastroenterol Hepatol
, vol.12
, pp. 1371-1380
-
-
Ioannou, G.N.1
Beste, L.A.2
Green, P.K.3
-
17
-
-
84893648933
-
Rates and predictors of response to anti-viral treatment for hepatitis c virus in hiv/hcv co-infection in a nationwide study of 619 patients
-
Ioannou GN, Scott JD, Yang Y, Green PK, Beste LA. Rates and predictors of response to anti-viral treatment for hepatitis C virus in HIV/HCV co-infection in a nationwide study of 619 patients. Aliment Pharmacol Ther 2013; 38:1373-1384
-
(2013)
Aliment Pharmacol Ther
, vol.38
, pp. 1373-1384
-
-
Ioannou, G.N.1
Scott, J.D.2
Yang, Y.3
Green, P.K.4
Beste, L.A.5
-
18
-
-
34547428001
-
Predictors of response of us veterans to treatment for the hepatitis c virus
-
Backus LI, Boothroyd DB, Phillips BR, Mole LA. Predictors of response of US veterans to treatment for the hepatitis C virus. Hepatology 2007; 46:37-47
-
(2007)
Hepatology
, vol.46
, pp. 37-47
-
-
Backus, L.I.1
Boothroyd, D.B.2
Phillips, B.R.3
Mole, L.A.4
-
19
-
-
84892737595
-
All-oral therapy with sofosbuvir plus ribavirin for the treatment of hcv genotype 1, 2, and 3 infection in patients co-infected with hiv (photon-1) [abstract 212
-
AASLD 2013); Washington DC
-
Sulkowski MS, Rodriguez-Torres M, Lalezari JP. All-oral therapy with sofosbuvir plus ribavirin for the treatment of HCV genotype 1, 2, and 3 infection in patients co-infected with HIV (PHOTON-1) [Abstract 212]. 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2013); Washington, DC, 2013
-
(2013)
64th Annual Meeting of the American Association for the Study of Liver Diseases
-
-
Sulkowski, M.S.1
Rodriguez-Torres, M.2
Lalezari, J.P.3
-
20
-
-
84878976866
-
Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis c genotype-1 infection (atomic): An open-label, randomised, multicentre phase 2 trial
-
Kowdley KV, Lawitz E, Crespo I, Hassanein T, Davis MN, DeMicco M, et al. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet 2013; 381:2100-2107
-
(2013)
Lancet
, vol.381
, pp. 2100-2107
-
-
Kowdley, K.V.1
Lawitz, E.2
Crespo, I.3
Hassanein, T.4
Davis, M.N.5
Demicco, M.6
-
21
-
-
84876740954
-
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis c infection: A randomised, double-blind, phase 2 trial
-
Lawitz E, Lalezari JP, Hassanein T, Kowdley KV, Poordad FF, Sheikh AM, et al. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis 2013; 13:401-408
-
(2013)
Lancet Infect Dis
, vol.13
, pp. 401-408
-
-
Lawitz, E.1
Lalezari, J.P.2
Hassanein, T.3
Kowdley, K.V.4
Poordad, F.F.5
Sheikh, A.M.6
-
22
-
-
84877730954
-
Sofosbuvir for previously untreated chronic hepatitis c infection
-
Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368:1878-1887
-
(2013)
N Engl J Med
, vol.368
, pp. 1878-1887
-
-
Lawitz, E.1
Mangia, A.2
Wyles, D.3
Rodriguez-Torres, M.4
Hassanein, T.5
Gordon, S.C.6
|